Related references
Note: Only part of the references are listed.Clinical efficacy and safety of cefiderocol for resistant Gram-negative infections: a real-life, single-centre experience
Arta Karruli et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2023)
Treatment and diagnosis of severe KPC-producing Klebsiella pneumoniae infections: a perspective on what has changed over last decades
Daniele Roberto Giacobbe et al.
ANNALS OF MEDICINE (2023)
Case series of cefiderocol for salvage therapy in carbapenem-resistant Gram-negative infections
Victoria Gavaghan et al.
INFECTION (2023)
Cefiderocol, a Siderophore Cephalosporin, as a Treatment Option for Infections Caused by Carbapenem-Resistant Enterobacterales
Keith S. Kaye et al.
INFECTIOUS DISEASES AND THERAPY (2023)
Cefiderocol for the Treatment of Infections Due to Metallo-B-lactamase-Producing Pathogens in the CREDIBLE-CR and APEKS-NP Phase 3 Randomized Studies
Jean-Francois Timsit et al.
CLINICAL INFECTIOUS DISEASES (2022)
Cefiderocol- Compared to Colistin-Based Regimens for the Treatment of Severe Infections Caused by Carbapenem-Resistant Acinetobacter baumannii
Marco Falcone et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)
In vitro and in vivo efficacy of cefiderocol plus tigecycline, colistin, or meropenem against carbapenem-resistant Acinetobacter baumannii
Wentao Ni et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2022)
Cefiderocol use in Gram negative infections with limited therapeutic options: Is combination therapy the key?
Silvia Corcione et al.
JOURNAL OF INFECTION AND PUBLIC HEALTH (2022)
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial
Matteo Bassetti et al.
LANCET INFECTIOUS DISEASES (2021)
Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial
Richard G. Wunderink et al.
LANCET INFECTIOUS DISEASES (2021)
US Food and Drug Administration (FDA): Benefit-Risk Considerations for Cefiderocol (Fetroja®)
Shabnam Naseer et al.
CLINICAL INFECTIOUS DISEASES (2021)
Cefiderocol-Based Combination Therapy for Difficult-to-Treat Gram-Negative Severe Infections: Real-Life Case Series and Future Perspectives
Davide Fiore Bavaro et al.
ANTIBIOTICS-BASEL (2021)
Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant Pseudomonas aeruginosa (DTR-P) infections
Marianna Meschiari et al.
JAC-ANTIMICROBIAL RESISTANCE (2021)
Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia
Mercedes Delgado-Valverde et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-Resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety
Young Ran Lee et al.
CLINICAL DRUG INVESTIGATION (2020)
Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli
George G. Zhanel et al.
DRUGS (2019)
Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections
Yohei Doi
CLINICAL INFECTIOUS DISEASES (2019)
In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study)
Krystyna M. Kazmierczak et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2019)
Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial
Simon Portsmouth et al.
LANCET INFECTIOUS DISEASES (2018)